Abstract
Based upon the recent advances in genetic association studies, the age of genetically based personalized medicine may be finally arriving in the near future for many diseases. The field of hematopoietic cell transplantation (HCT) is well ahead of this curve. In the entire field of medicine, there is no better demonstration of the power of personalized medicine than the use of patient-donor histocompatibility antigen (HLA) matching to improve stem cell transplant outcomes. Nevertheless, even the HCT field will benefit significantly from the latest developments in genetic association studies, which has allowed expanded analyses of the human genome beyond the major histocompatibility complex (MHC).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
